Leandra Serio, Antonella Paolucci, Maria Ester Carugno, Sofia Cappannari, Alessia Cecchini, Marianna Litterio, Rita Del Pinto, Claudio Ferri
{"title":"三个月的苯甲多酸治疗不影响基于胱抑素c的肾小球滤过率的估计。","authors":"Leandra Serio, Antonella Paolucci, Maria Ester Carugno, Sofia Cappannari, Alessia Cecchini, Marianna Litterio, Rita Del Pinto, Claudio Ferri","doi":"10.1007/s40292-025-00732-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Bempedoic acid can interfere with creatinine excretion, thereby potentially altering the calculation of glomerular filtration rate (eGFR), but is not known to have an effect on cystatin C metabolism.</p><p><strong>Aim: </strong>The aim of this pilot observational study was to assess the impact of 3-months bempedoic acid treatment on renal function assessed by serum creatinine and cystatin C.</p><p><strong>Methods: </strong>Consecutive hypercholesterolemic outpatients with indication to be started on bempedoic acid and available serum creatinine and cystatin C levels were enrolled. Follow-up (45-90 days) renal function markers were assessed. Lipid profile, uric acid levels, and CRP levels were also recorded.</p><p><strong>Results: </strong>Bempedoic acid reduced LDL-c and total cholesterol levels by day 45. No changes were observed in HDL-c, triglycerides, Lp(a), serum creatinine, eGFR<sub>cr</sub>, BUN, uric acid, or CRP levels throughout the study. The sensitivity analysis on individuals with complete data for cystatin C during follow-up (42%) confirmed the overall observations, while also showing neutral effects of bempedoic acid eGFR<sub>cys</sub> and eGFR<sub>cr-cys</sub>.</p><p><strong>Conclusions: </strong>Three-months administration of bempedoic acid did not affect cystatin C levels. Adequately powered studies are needed to test these findings and, ultimately, the renal safety of bempedoic acid.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"533-541"},"PeriodicalIF":2.9000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474684/pdf/","citationCount":"0","resultStr":"{\"title\":\"Three months of bempedoic acid treatment does not affect cystatin C-based estimation of glomerular filtration rate.\",\"authors\":\"Leandra Serio, Antonella Paolucci, Maria Ester Carugno, Sofia Cappannari, Alessia Cecchini, Marianna Litterio, Rita Del Pinto, Claudio Ferri\",\"doi\":\"10.1007/s40292-025-00732-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Bempedoic acid can interfere with creatinine excretion, thereby potentially altering the calculation of glomerular filtration rate (eGFR), but is not known to have an effect on cystatin C metabolism.</p><p><strong>Aim: </strong>The aim of this pilot observational study was to assess the impact of 3-months bempedoic acid treatment on renal function assessed by serum creatinine and cystatin C.</p><p><strong>Methods: </strong>Consecutive hypercholesterolemic outpatients with indication to be started on bempedoic acid and available serum creatinine and cystatin C levels were enrolled. Follow-up (45-90 days) renal function markers were assessed. Lipid profile, uric acid levels, and CRP levels were also recorded.</p><p><strong>Results: </strong>Bempedoic acid reduced LDL-c and total cholesterol levels by day 45. No changes were observed in HDL-c, triglycerides, Lp(a), serum creatinine, eGFR<sub>cr</sub>, BUN, uric acid, or CRP levels throughout the study. The sensitivity analysis on individuals with complete data for cystatin C during follow-up (42%) confirmed the overall observations, while also showing neutral effects of bempedoic acid eGFR<sub>cys</sub> and eGFR<sub>cr-cys</sub>.</p><p><strong>Conclusions: </strong>Three-months administration of bempedoic acid did not affect cystatin C levels. Adequately powered studies are needed to test these findings and, ultimately, the renal safety of bempedoic acid.</p>\",\"PeriodicalId\":12890,\"journal\":{\"name\":\"High Blood Pressure & Cardiovascular Prevention\",\"volume\":\" \",\"pages\":\"533-541\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474684/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"High Blood Pressure & Cardiovascular Prevention\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s40292-025-00732-x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"High Blood Pressure & Cardiovascular Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40292-025-00732-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
Three months of bempedoic acid treatment does not affect cystatin C-based estimation of glomerular filtration rate.
Introduction: Bempedoic acid can interfere with creatinine excretion, thereby potentially altering the calculation of glomerular filtration rate (eGFR), but is not known to have an effect on cystatin C metabolism.
Aim: The aim of this pilot observational study was to assess the impact of 3-months bempedoic acid treatment on renal function assessed by serum creatinine and cystatin C.
Methods: Consecutive hypercholesterolemic outpatients with indication to be started on bempedoic acid and available serum creatinine and cystatin C levels were enrolled. Follow-up (45-90 days) renal function markers were assessed. Lipid profile, uric acid levels, and CRP levels were also recorded.
Results: Bempedoic acid reduced LDL-c and total cholesterol levels by day 45. No changes were observed in HDL-c, triglycerides, Lp(a), serum creatinine, eGFRcr, BUN, uric acid, or CRP levels throughout the study. The sensitivity analysis on individuals with complete data for cystatin C during follow-up (42%) confirmed the overall observations, while also showing neutral effects of bempedoic acid eGFRcys and eGFRcr-cys.
Conclusions: Three-months administration of bempedoic acid did not affect cystatin C levels. Adequately powered studies are needed to test these findings and, ultimately, the renal safety of bempedoic acid.
期刊介绍：
High Blood Pressure & Cardiovascular Prevention promotes knowledge, update and discussion in the field of hypertension and cardiovascular disease prevention, by providing a regular programme of independent review articles covering key aspects of the management of hypertension and cardiovascular diseases. The journal includes: Invited ''State of the Art'' reviews. Expert commentaries on guidelines, major trials, technical advances.Presentation of new intervention trials design.''Pros and Cons'' or round tables on controversial issues.Statements on guidelines from hypertension and cardiovascular scientific societies.Socio-economic issues.Cost/benefit in prevention of cardiovascular diseases.Monitoring of healthcare systems.News and views from the Italian Society of Hypertension (including abstracts).All manuscripts are subject to peer review by international experts. Letters to the editor are welcomed and will be considered for publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
